Status
Conditions
Treatments
About
This is a clinical study without a formal hypothesis. The primary objective of the study is to evaluate the use of the Aurora Endometrial Ablation System in achieving a return to normal menstrual blood loss at 12 months post-treatment, in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete or no longer wish to retain fertility.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Refractory menorrhagia with no definable organic cause
Female subject from age 25 to 50 years
Uterine sound measurement of 6.0cm to 10.0cm (external os to internal fundus)
One of the following criteria:
A. Documented history of menorrhagia secondary to dysfunctional uterine bleeding (DUB).
B. If a pictorial blood loss assessment chart (PBLAC) scoring systems is used; a minimum PBLAC score of ≥150 for 3 months prior to study enrollment; OR, A minimum PBLAC score ≥150 for one month for women who either i. had at least 3 prior months documented failed medical therapy; or ii. had a contraindication to medical therapy; or iii. refused medical therapy
Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/ml
Not pregnant and no desire to be pregnant in the future
Patient agrees not to use hormonal contraception or any other medical intervention for bleeding during the study
Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC
Subject agrees to follow-up exams and data collection, including ability to accurately use menstrual diaries
Subject who is literate or demonstrates an understanding on how to use menstrual diaries or how to collect and provide used sanitary products
Exclusion criteria
Pregnancy or subject with a desire to conceive
Endometrial hyperplasia as confirmed by histology
Presence of active endometritis
Active pelvic inflammatory disease
Active sexually transmitted disease (STD), at the time of ablation. Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Patient may be considered for study enrollment.
Presence of bacteremia, sepsis, or other active systemic infection
Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure
Known/suspected gynecological malignancy within the past 5 years
Known clotting defects or bleeding disorders
Untreated/unevaluated cervical dysplasia (except CIN I)
Known/suspected abdominal/pelvic cancer
Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section)
Previous endometrial ablation procedure
Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma)
Currently on anticoagulants
Abnormal or obstructed cavity as confirmed by hysteroscopy or SIS, specifically:
Presence of an intrauterine device (IUD) which the patient is unwilling to have removed at the time of the operative visit
Presence of an implantable contraceptive device (e.g. Essure or Adiana).
Subject currently on hormonal birth control therapy or unwilling to use a non-hormonal birth control post-ablation (including a Mirena device).
Subject who is within 6-weeks post partum.
Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject
Any subject who is currently participating or considers future participation in any other research of an investigational drug or device.
Primary purpose
Allocation
Interventional model
Masking
24 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal